French COVID Cohort

Active, not recruiting

• Conditions: Coronavirus Infections

• Registration Number: NCT04262921
• Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary

Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing viral haemorrhagic fever (e.g. Ebola), and viruses that affect the central nervous system (CNS) such as TBEV \& Nipah require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.

In order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or host-directed therapies, the transmission dynamics, and factors underlying individual susceptibility.

The work proposed here may require sampling that will not immediately benefit the participants. It may also require analysis of the host genome, which may reveal other information about disease susceptibility or other aspects of health status.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-06
• Study First Submitted QC: 2020-02-07
• Study Start: 2020-02-08
• Study First Posted: 2020-02-10
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-29
• Last Update Posted: 2024-07-30
• Primary Completion: 2025-08-07
• Study Completion: 2025-08-07

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 4415

Inclusion Criteria

• Any patient admitted to a health care facility, with an infection confirmed by SARS-CoV-2 (virologically confirmed diagnosis by PCR).

Non inclusion criteria:

• Subject deprived of freedom, subject under a legal protective measure
• Refusal by participant, parent or appropriate representative.

Exclusion Criteria

• Confirmed diagnosis of another pathogen than SARS-CoV-2 and no indication or likelihood of co-infection with SARS-CoV-2.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical features	18 months	Describe the clinical features of the illness or syndrome (cardio-respiratory signs or symptoms, and laboratory results) and complications, and determinants of severity.; Assessment daily for 15 days, then weekly until max 100 days, then 3 and 6 months.
Response to treatment	18 months	Describe the response to treatments (including supportive care and novel therapeutics) by clinical, biological, radiological and virological assessments.; Assessment daily for 15 days, then weekly until max 100 days, then 3 and 6 months.
Pathogen replication, excretion and evolution, within the host	18 months	high-throughput sequencing of pathogen genomes obtained from respiratory tract, blood, urine, stool, CSF and other samples.; Assessment on Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11, Day 13, Day 15 then weekly until max 100 days, then 3 and 6 months.
Immune host responses to infection and therapy	18 months	Characterise the innate and acquired immune responses, circulating levels of immune signalling molecules and gene expression profiling in peripheral blood.; Assessment on Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11, Day 13, Day 15 then weekly until max 100 days, then 3 and 6 months.
Host genetic variants	Day 1	Identify host genetic variants associated with disease progression or severity

Trial Locations

Locations (97)

CHG Agen; 🇫🇷 Agen, France

Centre Hospitalier Du Pays D'aix; 🇫🇷 Aix-en-Provence, France

CHU Amiens; 🇫🇷 Amiens, France

CHU Angers; 🇫🇷 Angers, France

CH Annecy Genevois; 🇫🇷 Épagny, France

Hopital privé d'Antony; 🇫🇷 Antony, France

Hôpital de Mercy. CHR METZ-THIONVILLE; 🇫🇷 Ars-Laquenexy, France

Centre Hospitalier Henri Duffaut; 🇫🇷 Avignon, France

Chu Jean Minjoz; 🇫🇷 Besançon, France

Hôpital Avicenne AP-HP; 🇫🇷 Bobigny, France

Scroll for more (87 remaining)